Cracking the Genetic Code of Prostate Cancer | Prof Jyotsna Batra | CERI Seminar

Value of the Information & Strength of the Argument

The seminar offers substantial informational value for a specialised audience. It traces a complete research arc from population genetics to functional validation and early therapeutic development, which is uncommon in a single talk. The argumentation is generally rigorous: Batra explicitly distinguishes association from causation, acknowledges that GWAS effect sizes are very small, and stresses that computational predictions (miRNPs) required experimental validation. She presents a logical pipeline: GWAS → post-GWAS fine-mapping → functional annotation → microRNA target identification → in vitro and in vivo validation → small-molecule and nanoparticle development. The discussion of PSA limitations is balanced, noting overdiagnosis and the shift toward opportunistic testing. The four-microRNA panel is presented with the caveat that it was validated in European-ancestry cohorts, and the PSA variant story is nuanced, linking lower risk to lower PSA and poorer survival. The main weakness is the absence of quantitative details: no hazard ratios, p-values beyond illustrative examples, sample sizes, or effect sizes are given, which limits the ability to assess the strength of the evidence independently. The talk also relies heavily on unpublished or in-progress work, making it difficult to verify claims. Overall, the argumentation is coherent and self-critical, but the evidence is presented at a high level rather than with the granularity needed for critical appraisal.

Scientific Rigor, Source Quality, Title Accuracy

Scientific rigour is evident in the methodological transparency: Batra describes GWAS design, multiple-testing correction, fine-mapping, reporter assays, eQTL analysis, and mouse models. She appropriately flags limitations such as the European-ancestry bias in GWAS and the need for multi-ethnic studies. However, the talk does not cite specific publications, consortia names beyond PRACTICAL, or provide references for the 450 risk variants or the four-microRNA panel. No sources are listed in the description beyond the seminar host. The title, ‘Cracking the Genetic Code of Prostate Cancer’, is adequately matched to the content, though the phrase ‘cracking the code’ is somewhat hyperbolic for a field where much remains unresolved. The seminar is a single-lab narrative rather than a systematic review, so the quality of sources cannot be independently assessed from the transcript alone. The absence of a reference list is a notable gap for a research seminar.

The title matches the content well: the talk is indeed about germline genetics of prostate cancer, from GWAS to microRNA-based mechanisms and therapeutic leads. The 'cracking the genetic code' framing is somewhat promotional but not misleading.

7/10

The seminar presents a coherent research programme with explicit methodological steps (GWAS, post-GWAS fine-mapping, reporter assays, eQTL, mouse xenografts, nanoparticle formulation). Claims are framed with appropriate caveats (small effect sizes, European-ancestry bias, computational predictions requiring validation). However, no specific citations, effect sizes, confidence intervals or publication references are given in the transcript, and the talk is a single-lab perspective rather than a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction by the host and start of Prof Batra's talk.
• 03:00Overview of prostate cancer incidence and mortality, with emphasis on higher rates in South Africa.
• 07:00Explanation of the PSA test, its limitations, and the concept of overdiagnosis.
• 12:00Introduction to GWAS and the identification of ~450 risk variants, mostly in European populations.
• 18:00Discussion of post-GWAS fine-mapping and the challenge that most signals are non-coding.
• 25:00Explanation of microRNAs and miRNPs, and the identification of 16 miRNPs in seven genes.
• 35:00Functional validation of miRNPs using reporter gene assays and allele-specific regulation of PDK1.
• 45:00In vitro and in vivo testing of a microRNA mimic, showing reduced tumour growth and metastasis in mice.
• 55:00Development of DAP, a small molecule targeting glycolysis, and nanoparticle delivery.
• 1:00:00Presentation of a four-microRNA blood panel and a PSA gene variant linked to lower risk but poorer survival.